THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer.

ABSTRACT: Breast cancer remains the most prevalent cancer among women, with hormone receptor-positive (HR +) tumors accounting for approximately 70% of breast cancer cases. While the immune checkpoint inhibitor (ICI) anti-programmed cell death 1 (PD-1) pembrolizumab has demonstrated efficacy in triple-negative breast cancers (TNBCs), its benefit in HR + subtypes is limited. ICI resistance in breast cancer is largely due to a "cold" tumor immune microenvironment characterized by low tumor-infiltrating lymphocytes (TILs). To identify novel genetic determinants of immune exclusion and pembrolizumab resistance, we analyzed multi-omics and clinical datasets from the I-SPY2 clinical trial and The Cancer Genome Atlas (TCGA), focusing on genes associated with low T cell infiltration and poor response to pem

SUBMITTER: Walker OL 

PROVIDER: S-EPMC12570572 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature